Financial Ratios

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE124.451 (+0.81 %)
PREV CLOSE ( ) 123.45
OPEN PRICE ( ) 121.00
BID PRICE (QTY) 124.35 (4)
OFFER PRICE (QTY) 124.65 (4)
VOLUME 26428
TODAY'S LOW / HIGH ( )121.00 126.25
52 WK LOW / HIGH ( )69.78 155.45
NSE124.751.25 (+1.01 %)
PREV CLOSE( ) 123.50
OPEN PRICE ( ) 121.65
BID PRICE (QTY) 124.65 (109)
OFFER PRICE (QTY) 124.75 (265)
VOLUME 410210
TODAY'S LOW / HIGH( ) 121.65 126.45
52 WK LOW / HIGH ( )69.8 155.5
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.240.601.290.860.31
   CEPS(Rs)0.120.981.661.220.60
   DPS(Rs)0.000.000.500.000.20
   Book NAV/Share(Rs)40.1840.0241.1435.1136.41
   Tax Rate(%)37.625.6821.466.45-22.30
Margin Ratios
   Core EBITDA Margin(%)-11.73-5.438.928.931.61
   EBIT Margin(%)-3.217.8516.2112.145.66
   Pre Tax Margin(%)-4.337.1215.229.943.72
   PAT Margin (%)-2.706.7211.959.304.55
   Cash Profit Margin (%)1.3511.0715.3513.208.89
Performance Ratios
   ROA(%)-0.531.303.012.100.75
   ROE(%)-0.611.473.392.410.83
   ROCE(%)-0.681.654.452.960.99
   Asset Turnover(x)0.200.190.250.230.16
   Sales/Fixed Asset(x)2.012.042.662.663.00
   Working Capital/Sales(x)16.783.375.5512.2722.11
Efficiency Ratios
   Fixed Capital/Sales(x)0.500.490.380.380.33
   Receivable days53.5494.3169.4366.55132.93
   Inventory Days93.9794.2552.4445.1342.89
   Payable days126.58195.35206.34188.80148.84
Valuation Parameters
   PER(x)0.00224.56186.3190.43233.81
   PCE(x)596.59136.24145.0863.71119.79
   Price/Book(x)1.813.345.862.211.97
   Yield(%)0.000.000.210.000.28
   EV/Net Sales(x)8.2215.1422.568.6310.92
   EV/Core EBITDA(x)972.14123.67108.3653.30109.10
   EV/EBIT(x)-252.95192.24137.4470.42192.71
   EV/CE(x)1.602.895.291.961.76
   M Cap / Sales8.1315.1322.548.4910.67
Growth Ratio
   Net Sales Growth(%)1.39-17.2616.7736.7356.84
   Core EBITDA Growth(%)-93.00-51.3350.16121.09182.92
   EBIT Growth(%)-141.81-60.2956.45195.53793.18
   PAT Growth(%)-141.08-53.9250.48181.32444.19
   EPS Growth(%)-140.91-53.9250.49179.60439.93
Financial Stability Ratios
   Total Debt/Equity(x)0.020.020.010.040.05
   Current Ratio(x)1.191.731.501.181.09
   Quick Ratio(x)0.510.971.030.880.78
   Interest Cover(x)-2.8810.7516.265.532.93
   Total Debt/Mcap(x)0.010.000.000.020.02

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.